Aclaris Therapeutics Files 8-K

Ticker: ACRS · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1557746

Aclaris Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAclaris Therapeutics, INC. (ACRS)
Form Type8-K
Filed DateOct 14, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC filing, corporate disclosure

Related Tickers: ACRS

TL;DR

ACRS filed an 8-K. Standard disclosure, no major news yet.

AI Summary

Aclaris Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing does not contain specific transactional details or financial figures within the provided text, but indicates a standard corporate reporting event.

Why It Matters

This filing signifies a routine corporate disclosure by Aclaris Therapeutics, Inc. to the SEC, providing updates on company events and financial information as required.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for corporate reporting and does not contain information indicating significant risk or change.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report under Regulation FD and to include financial statements and exhibits as required by the SEC.

What is the exact name of the company filing this report?

The exact name of the company is Aclaris Therapeutics, Inc.

On what date was this report filed?

The report was filed on October 14, 2025.

In which state was Aclaris Therapeutics, Inc. incorporated?

Aclaris Therapeutics, Inc. was incorporated in Delaware.

What is the principal executive office address for Aclaris Therapeutics, Inc.?

The principal executive office address is 701 Lee Road, Suite 103, Wayne, PA 19087.

Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-10-14 06:59:22

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 14, 2025 at 8:00 a.m. ET, Aclaris Therapeutics, Inc. (the " Registrant ") will hold an in-person and virtual R&D Day. A webcast of the R&D Day will be available through the Events page of the Investors section of the Registrant's website. A copy of the presentation that will accompany the R&D Day is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant's filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Company Presentation. 104 The cover page from Aclaris Therapeutics, Inc.'s Form 8-K filed on October 14, 2025, formatted in Inline XBRL. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARIS THERAPEUTICS, INC. By: /s/ Kevin Balthaser Date: October 14, 2025 Kevin Balthaser Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing